Unknown

Dataset Information

0

Oral antiviral treatments for COVID-19: opportunities and challenges.


ABSTRACT: The use of antiviral COVID-19 medications can successfully inhibit SARS-CoV-2 replication and prevent disease progression to a more severe form. However, the timing of antiviral treatment plays a crucial role in this regard. Oral antiviral drugs provide an opportunity to manage SARS-CoV-2 infection without a need for hospital admission, easing the general burden that COVID-19 can have on the healthcare system. This review paper (i) presents the potential pharmaceutical antiviral targets, including various host-based targets and viral-based targets, (ii) characterizes the first-generation anti-SARS-CoV-2 oral drugs (nirmatrelvir/ritonavir and molnupiravir), (iii) summarizes the clinical progress of other oral antivirals for use in COVID-19, (iv) discusses ethical issues in such clinical trials and (v) presents challenges associated with the use of oral antivirals in clinical practice. Oral COVID-19 antivirals represent a part of the strategy to adapt to long-term co-existence with SARS-CoV-2 in a manner that prevents healthcare from being overwhelmed. It is pivotal to ensure equal and fair global access to the currently available oral antivirals and those authorized in the future.

SUBMITTER: Rahmah L 

PROVIDER: S-EPMC9309032 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC7833882 | biostudies-literature
| S-EPMC8754531 | biostudies-literature
| S-EPMC7661802 | biostudies-literature
| S-EPMC7738845 | biostudies-literature
| S-EPMC8416525 | biostudies-literature
| S-EPMC7773313 | biostudies-literature
| S-EPMC7405498 | biostudies-literature
| S-EPMC6487480 | biostudies-literature
| S-EPMC7405756 | biostudies-literature
| S-EPMC8131060 | biostudies-literature